● pepmg Research Desk · Peer-reviewed evidence review
What the research says about thymogen
A neutral summary of the peer-reviewed literature on thymogen, the synthetic Glu-Trp dipeptide immunomodulator, studied mostly in animal and cell models with human data limited to older, largely uncontrolled clinical reports and a single older placebo-controlled surgical trial. Research use only.
Limited evidence — Early or small human data, or strong preclinical work. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- Thymogen is described in the literature as a synthetic dipeptide, L-Glu-L-Trp, developed from an immunomodulatory molecule isolated from the thymus preparation Thymalin and studied as an immunostimulant [1][2].
- Most of the measured effects are preclinical: animal and cell studies report immunomodulating, antioxidant, reparative, and anti-carcinogenic activity [3][4][6][8].
- Human data are limited and mostly older and uncontrolled, though one older double-blind, placebo-controlled surgical trial reported fewer postoperative complications; there are no modern controlled efficacy trials [10].
- This page reports what the studies measured. It is not medical advice, an efficacy or safety claim, or dosing guidance. Research use only.
What thymogen is
Thymogen is characterized in the literature as a synthetic dipeptide composed of L-glutamic acid and L-tryptophan (L-Glu-L-Trp) and studied as an immunostimulant [1]. A 2024 review describes Thymogen and its mirror-image counterpart Thymodepressin (D-Glu-D-Trp), an immunosuppressor, as an example of two enantiomeric peptide drugs with opposite activities [1].
Earlier work reports that the L-Glu-L-Trp molecule was isolated from the natural thymus peptide complex Thymalin and then synthesized as the basis for Thymogen [2]. Material sold by third-party research-chemical vendors is offered for laboratory and research use only and is not an approved medicine.
What the research has measured
Limited evidenceMost of the interventional evidence is in animals. In female rats given the synthetic dipeptide over many months, one study reported a longer maximum lifespan in treated animals than in controls and lower total tumor incidence (about 1.5 times lower), malignant tumor incidence (about 1.7 times lower), and hematopoietic malignancy incidence (about 3.4 times lower) [3]. In a rat model of chemically induced esophagus and forestomach tumors, thymogen was reported to decrease tumor incidence by 12% and to lower tumor multiplicity about 1.7 times [6]. In rats exposed to radionuclides, thymogen was reported to inhibit radiation-induced carcinogenesis [7].
Other animal work describes reparative and antioxidant effects. In rats with carbon-tetrachloride liver injury, thymogen and structural analogues suppressed lipid peroxidation and stimulated regeneration of hepatocytes [4]. In a separate rat model of hydrazine-induced liver injury, thymogen and its analogues again reduced lipid peroxidation and stimulated hepatocyte regeneration [5].
Human evidence is limited. In cultured human peripheral blood lymphocytes, low concentrations of thymogen did not reduce dividing activity and showed no mutagenic activity, while reducing formaldehyde-induced chromosome aberrations [8]. In the human monocytic THP-1 cell line, the Thymogen dipeptide was among peptides that modulated proliferative signaling and inhibited lipopolysaccharide-stimulated inflammatory cytokines [9]. In an older double-blind, randomized, placebo-controlled trial in elderly patients before abdominal-tumor surgery, thymogen was reported to improve cellular-immunity parameters and to be associated with fewer postoperative complications than placebo [10]. Apart from that older trial, the human record is mostly uncontrolled.
What the trials report on safety and adverse events
Limited evidenceThere are no modern controlled human trials of administered thymogen from which to report human adverse-event rates. One older double-blind, randomized, placebo-controlled surgical trial reported fewer and less varied postoperative complications with thymogen than with placebo, but did not report a structured adverse-event breakdown in its abstract [10].
Genotoxicity-type testing in cultured human lymphocytes described no mutagenic activity at low concentrations, while high concentrations reduced lymphocyte proliferation [8]. In animals, the published work describes reparative and anti-carcinogenic effects rather than overt toxicity: liver-injury models reported reduced lipid peroxidation and hepatocyte regeneration, and one hepatopathy study noted that increasing the dose did not further increase activity [4][5].
Because the human data are limited and mostly uncontrolled and the interventional data are largely preclinical, nothing here should be read as a safety guarantee for people. Material sold by research-chemical vendors is not a regulated medicine. This is not medical advice; consult a qualified professional and read the studies directly.
How strong is the evidence
The evidence for thymogen is characterized as limited: there is a body of animal and cell-culture work on its immunomodulating, antioxidant, reparative, and anti-carcinogenic actions, plus mostly older and uncontrolled human clinical reports and one older double-blind, placebo-controlled surgical trial, but no modern controlled efficacy trials of thymogen [3][8][10]. "Limited" describes the design and scope of the published studies, not an endorsement, and the scope matters: most findings are in animals and cultured cells, and the human data are old and thin.
Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.
Sources · 10
- The First Reciprocal Activities of Chiral Peptide Pharmaceuticals: Thymogen and Thymodepressin, as Examples.
- Natural and synthetic thymic peptides as therapeutics for immune dysfunction.
- Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats.
- Reparative and Antioxidant Effects of New Analogues of Immunomodulator Thymogen in Experimental Model of Liver Damage.
- Hepatoprotective Effects of Thymogen Analogues in Hydrazine Hepatopathy in Rats.
- [Inhibiting effect of thymogen on the development of tumors of the esophagus and forestomach induced by N-nitrososarcosine ethyl ester in rats].
- [The effect of the synthetic immunomodulator thymogen on radiation-induced carcinogenesis in rats].
- [The effect of thymogen on the chromosome aberration level in a culture of human peripheral blood lymphocytes].
- Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line.
- [Application thymogen for preoperative preparation of elderly patients with tumor processes in abdominal cavity].
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.